Samsung Biologics Completes Payment for 3.2 Trillion KRW Rights Offering to Shareholders
[Asia Economy Reporter Lee Jung-yoon] Samsung Biologics announced on the 15th that the payment for the registered common stock rights offering worth 3.2008 trillion KRW has been completed.
Hot Picks Today
!["Stock Set to Double: This Company Smiles Every Time a Data Center Is Built [Click e-Stock]"](https://cwcontent.asiae.co.kr/asiaresize/93/2026050416112750184_1777878687.jpg)
"Stock Set to Double: This Company Smiles Every...
- "Continuous Groundwater Extraction Causes Mexico City of 22 Million to Sink by 2...
- "Is Yours Just Gathering Dust at Home? Millennials & Gen Z Rediscover Digicams O...
- "Going to Seongsu-dong?" Japanese Girl Group Faces Taxi Refusal in Seoul
- "Prime Minister in Underwear?"... Italy's Meloni Posts Herself to Warn of Deepfa...
The number of shares to be issued is 5,009,000, and the new shares are scheduled to be listed on the 28th.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
